Evonik's Dual Strategy: Beauty Innovations and Methionine Surge Counter Near-Term Headwinds

Evonik's Q1 EBITDA may fall 18%, but shares rise 23% YTD on methionine price surge, Care segment innovation, and a €400M cost-cutting program.

As Evonik Industries prepares to release its first-quarter figures on May 8, the specialty chemicals group is presenting a study in contrasts. While analysts at Deutsche Bank forecast an 18% year-on-year decline in EBITDA to €461 million, citing lower margins and unfavorable currency effects, the company is simultaneously showcasing high-margin growth initiatives at a major cosmetics trade fair in Paris. This juxtaposition of near-term pressure and strategic positioning is shaping a complex investment narrative.

The market appears to be looking beyond the imminent quarterly dip. Evonik's share price has risen a solid 23% since the start of the year, closing at €16.40 on Wednesday, even as it reflects the broader challenges of the ongoing corporate restructuring over a 12-month horizon. This resilience is underpinned by significant analyst upgrades focused on future catalysts.

A primary driver of optimism is the dynamics in the methionine market. Supply disruptions among Asian producers are forcing global buyers to seek alternatives, pushing prices higher in Europe and China. This trend has prompted several major banks to revise their targets upward. Goldman Sachs raised its price target to €20 from €18, reiterating a Buy recommendation. Similarly, Barclays maintained its Overweight rating with a €17 target, lifting its 2026 EBITDA estimate to €1.89 billion. Deutsche Bank analyst Virginie Boucher-Ferte also increased her target to €15 from €13, noting her estimates remain slightly above consensus despite the expected first-quarter weakness.

Parallel to this commodity-driven story, Evonik is aggressively promoting its value-added Care business. At the in-cosmetics Global fair in Paris, the company unveiled a revamped brand identity and new biotechnology products. These include bio-based film formers for sun care and sustainably derived ester oils with a reduced carbon footprint. To bolster its presence in a key growth region, Evonik is advancing plans for an innovation center in Shanghai, scheduled for 2026, aimed at developing localized cosmetic solutions for the Asian market.

Supporting the medium-term financial outlook is the comprehensive "Evonik Tailor Made" transformation program. The plan to cut up to 2,000 positions globally is expected to deliver annual savings of €400 million by the end of 2026. The company also benefits from strategic hedges, having secured long-term contracts for approximately 80% of its energy needs. A high local production rate in the important US market provides additional insulation from potential new tariff burdens.

On the product innovation front beyond cosmetics, Evonik recently launched "VESTAKEEP Easy Slide 2," a new high-performance material for plain bearings designed to withstand extreme temperatures and pressures, targeting specialized industrial, medical technology, and robotics applications.

For the full 2026 fiscal year, management continues to target an adjusted EBITDA between €1.7 billion and €2.0 billion. Starting this financial year, a new dividend policy will take effect, committing to distribute 40% to 60% of adjusted net income to shareholders. The upcoming quarterly report will offer the next concrete data point on how effectively price increases in the methionine business are beginning to offset broader margin pressures.